ASCO 2026 Radioligand Therapy Advances Across Prostate CancerSent on 02 June 2026
ASCO 2026 Advancing Curative Strategies in Bladder and Kidney CancerSent on 01 June 2026
Key Prostate Cancer Insights From Day 3 at ASCOSent on 31 May 2026
ASCO 2026 Matching Prostate Cancer Treatment to Risk, Response, and Patient BenefitSent on 31 May 2026
Novel Approaches to Curing Bladder and Kidney Cancer at ASCO 2026Sent on 30 May 2026
Emerging RCC and Bladder Cancer Data From ASCO Day 1Sent on 30 May 2026
Key GU Oncology Data to Watch at ASCO 2026Sent on 26 May 2026
What to Expect from UroToday Coverage at the Upcoming ASCO 2023 Annual Meeting Sent on 29 May 2023
Innovative Immune Approaches in Prostate Cancer - Case-Based Review of CAR T, BiTES and Next-Generation Agents: ASCO 2022 Sent on 09 June 2022
Local and Focal: What’s Next in Salvage Therapy? - Prostate Cancer Highlights from the 2022 ASCO Annual MeetingSent on 09 June 2022
Equitable Care in Prostate Cancer - Highlights from the 2022 ASCO Annual MeetingSent on 07 June 2022
ASCO 2022 Highlights in Advanced Prostate CancerSent on 06 June 2022
ASCO 2022 - Oral Abstracts in Metastatic Castration-Resistant Prostate Cancer and Making Sense of the Intensified mHSPC LandscapeSent on 05 June 2022
ASCO 2022 Best Approaches and Updates for Prostate Cancer Biochemical Recurrence and Bladder and Kidney Cancer HighlightsSent on 05 June 2022
ASCO 2022 Genitourinary Cancer Highlights - Long-Term Outcomes in Patients with Advanced Urothelial Carcinoma, Outcomes With Novel Combinations in Non-Clear Cell RCC and MoreSent on 04 June 2022
Early Highlights from Day 2 of the 2022 American Society of Clinical Oncology Annual Meeting and Orals in Bladder and Kidney CancerSent on 04 June 2022
ASCO 2022 Breaking Kidney and Bladder Cancer OralsSent on 03 June 2022
Written Coverage Begins Friday, June 3 - Looking Forward to the 2022 American Society of Clinical Oncology (ASCO) Meeting Sent on 31 May 2022
Display #
Results 1 - 18 out of 18